BioRestorative Therapies Inc (NASDAQ: BRTX) has experienced a rise in its stock price by 13.16% compared to its previous closing price of $1.52. However, the company has seen a gain of 3.27% in its stock price over the last five trading days. globenewswire.com reported 2025-06-18 that MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Wednesday, June 18, 2025, at 10:50 a.m. Eastern time.
Is It Worth Investing in BioRestorative Therapies Inc (NASDAQ: BRTX) Right Now?
Moreover, the 36-month beta value for BRTX is 76.75. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BRTX is 5.43M and currently, short sellers hold a 4.81% of that float. On July 09, 2025, BRTX’s average trading volume was 104.50K shares.
BRTX’s Market Performance
BRTX stock saw a decrease of 3.27% in the past week, with a monthly decline of -3.38% and a quarterly a decrease of 1.17%. The volatility ratio for the week is 5.57%, and the volatility levels for the last 30 days are 7.08% for BioRestorative Therapies Inc (BRTX). The simple moving average for the past 20 days is 1.91% for BRTX’s stock, with a -0.42% simple moving average for the past 200 days.
BRTX Trading at 0.19% from the 50-Day Moving Average
After a stumble in the market that brought BRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.55% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BRTX starting from Broadrick Dale, who sale 1,112 shares at the price of $1.58 back on Oct 28 ’24. After this action, Broadrick Dale now owns 445,933 shares of BioRestorative Therapies Inc, valued at $1,757 using the latest closing price.
Stock Fundamentals for BRTX
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- 0.92 for the gross margin
The net margin for BioRestorative Therapies Inc stands at -30.94. The total capital return value is set at -1.99. Equity return is now at value -117.16, with -85.55 for asset returns.
Currently, EBITDA for the company is -11.37 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 29.87. The receivables turnover for the company is 15.64for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.23.
Conclusion
To wrap up, the performance of BioRestorative Therapies Inc (BRTX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
